Alnylam Pharmaceuticals this week released an update for its key financial and clinical goals for 2010. However, the guidance was primarily a confirmation of previous estimates.

"We are … excited about the next 12 to 18 months as we … fulfill the RNAi 2010 goals that we described two years ago," Alnylam President and COO Barry Greene said in a statement. "Over this period, we expect to have four RNAi therapeutic programs in clinical development … providing us with the opportunity to demonstrate human proof of concept for multiple programs."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.